On January 12th, the 43rd Annual J.P. Morgan Healthcare Conference (JPM Conference), an influential investment seminar, took place in San Francisco. Sungen Biomedical made a notable presentation featuring SGC001, the world’s first antibody drug for the treatment of acute myocardial infarction (AMI). During the conference, Dr. Wei Zeng, representing Sungen Biomedical, provided an overview of the latest clinical advancements in SGC001 project.
Cardiovascular disease remains the leading cause of death world widely, accounting for about one-third of all deaths. About 2.5 million people die of heart attacks in China each year. SGC001 is the world's first monoclonal antibody drug for AMI developed by Sungen Biomedical. It can block the apoptosis of cardiomyocytes induced by target molecules, reduce the oxidative stress damage of cardiomyocytes, inhibit downstream inflammatory response, promote blood perfusion in ischemic areas, and reduce the size of myocardial infarction. Preclinical study data show that SGC001 has obvious therapeutic effects on heart failure and remodeling after MI, and can significantly reduce the death rate of MI. SGC001 has been approved by the US FDA and China NMPA for clinical trials, and the current phase I study shows that it has a good safety. SGC001 will break through the limitations of existing AMI therapy and bring more hopes to patients.
Sungen Biomedical's appearance at this JPM event, with its innovative technology platform and differentiated R&D pipeline, not only attracted the attention of global investment institutions, but also demonstrated the company's scientific and technological innovation strength. It lays a solid foundation for its future global layout, cooperative development and market expansion. Focusing on uncovered medical needs, Sungen Biomedical will collaborate with international partners to provide more treatment options for patients around the world.
As the most prestigious industry summit in the world, JPM Conference was coming as expected this year. It is the largest and most influential, international, health-investment, financing seminar and business development conference in the global medical industry, bringing together the world's top pharmaceutical companies, innovative company experts and investment professionals.
Sungen Biomedical is an innovation-driven biomedical company dedicated to the discovery, development and commercialization of original (FIC) antibody drugs. With excellent scientific research and innovative drug development capabilities, guided by unmet clinical needs, Sungen has built a series of international-level technological platforms, and established a number of original biological macromolecule product pipelines with great market potential, involving the treatment of cardiovascular and cerebrovascular diseases, tumors, neurodegeneration and other diseases.
Updated: Mar 19, 2025
